Azacitidine for the treatment of patients with acute myeloid leukemia with 20%–30% blasts and multilineage dysplasia
- 215 Downloads
Azacitidine is approved in the EU for the treatment of adult patients who are not candidates for allogeneic stem cell transplantation, and who have intermediate-2 risk or high-risk myelodysplastic syndromes, according to the International Prognostic Scoring System. The approval includes the treatment of patients with acute myeloid leukemia (AML) with 20%–30% blasts and multilineage dysplasia, according to the World Health Organization (WHO) classification. This review focuses on the outcomes with azacitidine in this latter group of patients, previously classified as refractory anemia with excess of blasts in transformation, as defined by the French-American-British classification criteria. The main clinical evidence is based on the results of two large phase III clinical trials (Cancer and Leukemia Group B 9221, and AZA-001). The AZA-001 trial shows azacitidine significantly prolongs median overall survival in older patients with low marrow blasts (20%–30%) according to WHO-defined AML, and significantly improved several patient morbidity measures, compared with conventional care regimens. In addition, the review examines the results of azacitidine in combination with other treatments currently used in AML.
Keywordsazacitidine acute myeloid leukemia myelodysplastic syndromes
- 5.EPAR-Product Information. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000978/WC500050239.pdf). Accessed February 1, 2011.
- 7.National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia. V.2.2011. Available at: http://www.nccn.org/professionals/physician_gls. Accessed January 30, 2011.
- 11.Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007;109:5129–5135.PubMedCrossRefGoogle Scholar
- 21.Thépot S, Itzykson R, Seegers V, et al. Azacytidine (AZA) as first line therapy in AML: results of the French ATU program. Blood (ASH Annual Meeting Abstracts). 2009;114:843.Google Scholar
- 22.Itzykson R, Thépot S, Recher C, et al. Azacytidine in refractory or relapsed AML after intensive chemotherapy (IC): results of the French ATU program. Blood (ASH Annual Meeting Abstracts). 2009;114:1054.Google Scholar
- 25.Gardin C, Prébet T, Bouabdallah K, et al. A phase II study of post-remission therapy with azacitidine (AZA) in patients with AML post-MDS and highrisk MDS: a GFM group study. Blood (ASH Annual Meeting Abstracts). 2009;114:844.Google Scholar
- 27.Nand S, Godwin J, Smith S, et al. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leuk Lymphoma. 2008;49:2141–2147.PubMedCrossRefGoogle Scholar
- 29.Silverman LR, Verma A, Odchimar-Reissig R, et al. A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: a New York Cancer Consortium. J Clin Oncol. 2008;26(suppl.). Abstract 7000.Google Scholar
- 31.Vigil C, Cortes J, Kantarjian H, Garcia-Manero G, Lancet E, List A. Hypomethylating therapy for the treatment of acute erythroleukemia patients. Blood (ASH Annual Meeting Abstracts). 2009;114:2069.Google Scholar
- 33.National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic Syndromes. V.2.2010. Available at: http://www.nccn.org/professionals/physician_gls. Accessed January 30, 2011.